Table 1.
Clinicopathological characteristics of the entire cohort (n = 2352).
| Variables | PNI < 43.9 group (n = 633) | PNI ≥ 43.9 group (n = 1719) | P value |
|---|---|---|---|
| Gender (males) | 437 (60.9%) | 1126 (65.5%) | 0.107 |
| Age (years) | 59.29 ± 10.54 | 54.85 ± 10.60 | 0.848 |
| Body Mass Index (kg/m2) | 20.90 ± 2.84 | 22.10 ± 3.06 | 0.010 |
| American Society of Anesthesiology score | <0.001 | ||
| 1 | 71 (11.2%) | 261 (15.2%) | |
| 2 | 439 (63.4%) | 1340 (78.0%) | |
| 3 | 120 (19.0%) | 112 (6.5%) | |
| 4 | 3 (0.5%) | 6 (0.3%) | |
| Any comorbidities | 224 (35.4%) | 481 (28.0%) | 0.001 |
| Neo-adjuvant chemotherapy | 57 (9.0%) | 201 (11.7%) | 0.064 |
| Pre-operative lymphocyte count (×109/L) | 1.31 ± 0.43 | 1.90 ± 0.67 | <0.001 |
| Pre-operative albumin (g/L) | 33.45 ± 3.27 | 40.70 ± 3.52 | 0.001 |
| Pre-operative hemoglobin (g/L) | 101.33 ± 24.5 | 122.78 ± 23.13 | 0.002 |
| Operation method | <0.001 | ||
| Open | 534 (84.4%) | 1231 (71.6%) | |
| Laparoscopy | 99 (15.6%) | 488 (28.4%) | |
| Type of resection | 0.743 | ||
| Subtotal gastrectomy | 458 (72.4%) | 1232 (71.7%) | |
| Total gastrectomy | 175 (27.6%) | 487 (28.3%) | |
| Tumor size (cm) | 5.12 ± 2.07 | 4.35 ± 1.94 | 0.095 |
| Tumor location | 0.031 | ||
| Upper | 55 (8.7%) | 171 (9.9%) | |
| Middle | 140 (22.1%) | 448 (26.1%) | |
| Lower | 406 (64.1%) | 1044 (60.7%) | |
| Diffuse | 32 (5.1%) | 55 (3.2%) | |
| pTNM stage* | 0.004 | ||
| II | 139 (22.0%) | 480 (27.9%) | |
| III | 494 (78.0%) | 1239 (72.1%) | |
| Intra-operative blood loss (mL) | 218 ± 153 | 206 ± 128 | 0.001 |
| Operation time (min) | 202 ± 54 | 202 ± 55 | 0.882 |
| Peri-operative blood transfusion | <0.001 | ||
| Yes | 256 (40.4%) | 287 (16.7%) | |
| No | 377 (59.6%) | 1432 (83.3%) | |
| Post-operative complications classification† | <0.001 | ||
| None | 535 (84.5%) | 1562 (90.9%) | |
| Infectious complications | 59 (9.3%) | 101 (5.9%) | |
| Non-infectious complications | 39 (6.2%) | 56 (3.3%) | |
| Post-operative complications severity† | <0.001 | ||
| None | 535 (84.5%) | 1562 (90.9%) | |
| Grade II | 69 (10.9%) | 95 (5.5%) | |
| Grade III or greater | 29 (4.9%) | 62 (3.6%) | |
| Requirement of Intensive Care Unit care | 22 (3.5%) | 44 (2.6%) | 0.233 |
| Post-operative hospital stays (days) | 11.50 ± 5.21 | 10.70 ± 5.82 | 0.838 |
| Peri-operative adjuvant chemotherapy | <0.001 | ||
| None | 229 (36.2%) | 424 (24.7%) | |
| 1–5 cycles | 271 (42.8%) | 741 (43.1%) | |
| ≥6 cycles | 133 (21.0%) | 554 (32.2%) |
PNI prognostic nutritional index.
Data are presented as mean ± SD or n (%).
*Tumor stages are based on 8th edition of the Union for International Cancer Control TNM classification.
†Defined as Clavien–Dindo grade II or greater. Patients who developed both infectious and non-infectious complications were classified into the infectious group.